1. Generics Bulletin
  3. >>Biosimilars

Frontrunner Amgen Expects US Biosimilars To ‘Shift Significantly’ With Adalimumab

Firm Prepares To Launch First Humira Biosimilar At A ‘Pivotal Time’ For The US Market

 
• By Dave Wallace

Amgen expects a significant shift in the US biosimilars landscape as Humira rivals launch next year, Chad Pettit, the firm’s executive director of marketing and global biosimilars lead, tells Generics Bulletin. The company expects to be first to market with its version of adalimumab from the end of January 2023, helping to drive long-term growth ambitions for its biosimilars business.

Paradigm Shift Sign
Humira biosimilars will shift the US market significantly • Source: Shutterstock

The advent of biosimilar competition to Humira (adalimumab) will mark a significant shift in the US biosimilars market, Amgen believes, as the firm prepares to lead the charge with a late January 2023 launch of its Amjevita (adalimumab-atto) version.

In the second part of an exclusive interview with Generics Bulletin, Amgen executive director of marketing and global biosimilars lead...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products